134 related articles for article (PubMed ID: 9804700)
21. Potent, brain-penetrant, hydroisoindoline-based human neurokinin-1 receptor antagonists.
Jiang J; Bunda JL; Doss GA; Chicchi GG; Kurtz MM; Tsao KL; Tong X; Zheng S; Upthagrove A; Samuel K; Tschirret-Guth R; Kumar S; Wheeldon A; Carlson EJ; Hargreaves R; Burns D; Hamill T; Ryan C; Krause SM; Eng W; DeVita RJ; Mills SG
J Med Chem; 2009 May; 52(9):3039-46. PubMed ID: 19354254
[TBL] [Abstract][Full Text] [Related]
22. Correlation of neurokinin (NK) 1 receptor occupancy in gerbil striatum with behavioral effects of NK1 antagonists.
Duffy RA; Varty GB; Morgan CA; Lachowicz JE
J Pharmacol Exp Ther; 2002 May; 301(2):536-42. PubMed ID: 11961054
[TBL] [Abstract][Full Text] [Related]
23. Efficient synthesis of NK(1) receptor antagonist aprepitant using a crystallization-induced diastereoselective transformation.
Brands KM; Payack JF; Rosen JD; Nelson TD; Candelario A; Huffman MA; Zhao MM; Li J; Craig B; Song ZJ; Tschaen DM; Hansen K; Devine PN; Pye PJ; Rossen K; Dormer PG; Reamer RA; Welch CJ; Mathre DJ; Tsou NN; McNamara JM; Reider PJ
J Am Chem Soc; 2003 Feb; 125(8):2129-35. PubMed ID: 12590540
[TBL] [Abstract][Full Text] [Related]
24. Neurokinin 1 receptor antagonists: correlation between in vitro receptor interaction and in vivo efficacy.
Lindström E; von Mentzer B; Påhlman I; Ahlstedt I; Uvebrant A; Kristensson E; Martinsson R; Novén A; de Verdier J; Vauquelin G
J Pharmacol Exp Ther; 2007 Sep; 322(3):1286-93. PubMed ID: 17575073
[TBL] [Abstract][Full Text] [Related]
25. SSR240600 [(R)-2-(1-[2-[4-[2-[3,5-bis(trifluoromethyl)phenyl]acetyl]-2-(3,4-dichlorophenyl)-2-morpholinyl]ethyl]-4-piperidinyl)-2-methylpropanamide], a centrally active nonpeptide antagonist of the tachykinin neurokinin 1 receptor: II. Neurochemical and behavioral characterization.
Steinberg R; Alonso R; Rouquier L; Desvignes C; Michaud JC; Cudennec A; Jung M; Simiand J; Griebel G; Emonds-Alt X; Le Fur G; Soubrié P
J Pharmacol Exp Ther; 2002 Dec; 303(3):1180-8. PubMed ID: 12438542
[TBL] [Abstract][Full Text] [Related]
26. Molecular cloning, mutations and effects of NK1 receptor antagonists reveal the human-like pharmacology of gerbil NK1 receptors.
Engberg S; Ahlstedt I; Leffler A; Lindström E; Kristensson E; Svensson A; Påhlman I; Johansson A; Drmota T; von Mentzer B
Biochem Pharmacol; 2007 Jan; 73(2):259-69. PubMed ID: 17097619
[TBL] [Abstract][Full Text] [Related]
27. Pharmacological characterization of T-2328, 2-fluoro-4'-methoxy-3'-[[[(2S,3S)-2-phenyl-3-piperidinyl]amino]methyl]-[1,1'-biphenyl]-4-carbonitrile dihydrochloride, as a brain-penetrating antagonist of tachykinin NK1 receptor.
Watanabe Y; Asai H; Ishii T; Kiuchi S; Okamoto M; Taniguchi H; Nagasaki M; Saito A
J Pharmacol Sci; 2008 Jan; 106(1):121-7. PubMed ID: 18187929
[TBL] [Abstract][Full Text] [Related]
28. Characterization of the binding and activity of a high affinity, pseudoirreversible morpholino tachykinin NK1 receptor antagonist.
Cascieri MA; Ber E; Fong TM; Hale JJ; Tang F; Shiao LL; Mills SG; MacCoss M; Sadowski S; Tota MR; Strader CD
Eur J Pharmacol; 1997 May; 325(2-3):253-61. PubMed ID: 9163573
[TBL] [Abstract][Full Text] [Related]
29. Discovery and biological characterization of (2R,4S)-1'-acetyl-N-{(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-2-(4-fluoro-2-methylphenyl)-N-methyl-4,4'-bipiperidine-1-carboxamide as a new potent and selective neurokinin 1 (NK1) receptor antagonist clinical candidate.
Di Fabio R; Alvaro G; Griffante C; Pizzi DA; Donati D; Mattioli M; Cimarosti Z; Guercio G; Marchioro C; Provera S; Zonzini L; Montanari D; Melotto S; Gerrard PA; Trist DG; Ratti E; Corsi M
J Med Chem; 2011 Feb; 54(4):1071-9. PubMed ID: 21229983
[TBL] [Abstract][Full Text] [Related]
30. Pharmacological characterization of ZD6021: a novel, orally active antagonist of the tachykinin receptors.
Rumsey WL; Aharony D; Bialecki RA; Abbott BM; Barthlow HG; Caccese R; Ghanekar S; Lengel D; McCarthy M; Wenrich B; Undem B; Ohnmacht C; Shenvi A; Albert JS; Brown F; Bernstein PR; Russell K
J Pharmacol Exp Ther; 2001 Jul; 298(1):307-15. PubMed ID: 11408556
[TBL] [Abstract][Full Text] [Related]
31. In vitro and in vivo predictors of the anti-emetic activity of tachykinin NK1 receptor antagonists.
Rupniak NM; Tattersall FD; Williams AR; Rycroft W; Carlson EJ; Cascieri MA; Sadowski S; Ber E; Hale JJ; Mills SG; MacCoss M; Seward E; Huscroft I; Owen S; Swain CJ; Hill RG; Hargreaves RJ
Eur J Pharmacol; 1997 May; 326(2-3):201-9. PubMed ID: 9196273
[TBL] [Abstract][Full Text] [Related]
32. Cellular and behavioural profile of the novel, selective neurokinin1 receptor antagonist, vestipitant: a comparison to other agents.
Brocco M; Dekeyne A; Mannoury la Cour C; Touzard M; Girardon S; Veiga S; de Nanteuil G; deJong TR; Olivier B; Millan MJ
Eur Neuropsychopharmacol; 2008 Oct; 18(10):729-50. PubMed ID: 18657401
[TBL] [Abstract][Full Text] [Related]
33. The tachykinin NK3 receptor agonist senktide induces locomotor activity in male Mongolian gerbils.
Nordquist RE; Durkin S; Jacquet A; Spooren W
Eur J Pharmacol; 2008 Dec; 600(1-3):87-92. PubMed ID: 18930726
[TBL] [Abstract][Full Text] [Related]
34. Pharmacological characterization of a new, orally active and potent allosteric metabotropic glutamate receptor 1 antagonist, 4-[1-(2-fluoropyridin-3-yl)-5-methyl-1H-1,2,3-triazol-4-yl]-N-isopropyl-N-methyl-3,6-dihydropyridine-1(2H)-carboxamide (FTIDC).
Suzuki G; Kimura T; Satow A; Kaneko N; Fukuda J; Hikichi H; Sakai N; Maehara S; Kawagoe-Takaki H; Hata M; Azuma T; Ito S; Kawamoto H; Ohta H
J Pharmacol Exp Ther; 2007 Jun; 321(3):1144-53. PubMed ID: 17360958
[TBL] [Abstract][Full Text] [Related]
35. In vitro and in vivo pharmacological characterization of the novel NK₁ receptor selective antagonist Netupitant.
Rizzi A; Campi B; Camarda V; Molinari S; Cantoreggi S; Regoli D; Pietra C; Calo' G
Peptides; 2012 Sep; 37(1):86-97. PubMed ID: 22732666
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics and brain penetration of casopitant, a potent and selective neurokinin-1 receptor antagonist, in the ferret.
Minthorn E; Mencken T; King AG; Shu A; Rominger D; Gontarek RR; Han C; Bambal R; Davis CB
Drug Metab Dispos; 2008 Sep; 36(9):1846-52. PubMed ID: 18556439
[TBL] [Abstract][Full Text] [Related]
37. Anti-emetic activity of the novel nonpeptide tachykinin NK1 receptor antagonist ezlopitant (CJ-11,974) against acute and delayed cisplatin-induced emesis in the ferret.
Tsuchiya M; Fujiwara Y; Kanai Y; Mizutani M; Shimada K; Suga O; Ueda S; Watson JW; Nagahisa A
Pharmacology; 2002 Nov; 66(3):144-52. PubMed ID: 12372904
[TBL] [Abstract][Full Text] [Related]
38. Pharmacological properties of FK886, a new, centrally active neurokinin-1 receptor antagonist.
Yoshino-Furukawa T; Maeda Y; Kikuchi A; Sakuma H; Imazumi K; Yamakuni H; Sogabe H; Matsuo M; Manda T; Uchida W
Biol Pharm Bull; 2013; 36(1):76-81. PubMed ID: 23302639
[TBL] [Abstract][Full Text] [Related]
39. Pharmacological characterization of MK-0974 [N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)azepan-3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide], a potent and orally active calcitonin gene-related peptide receptor antagonist for the treatment of migraine.
Salvatore CA; Hershey JC; Corcoran HA; Fay JF; Johnston VK; Moore EL; Mosser SD; Burgey CS; Paone DV; Shaw AW; Graham SL; Vacca JP; Williams TM; Koblan KS; Kane SA
J Pharmacol Exp Ther; 2008 Feb; 324(2):416-21. PubMed ID: 18039958
[TBL] [Abstract][Full Text] [Related]
40. 3-Aryl-1,2-diacetamidopropane derivatives as novel and potent NK-1 receptor antagonists.
Hipskind PA; Howbert JJ; Bruns RF; Cho SS; Crowell TA; Foreman MM; Gehlert DR; Iyengar S; Johnson KW; Krushinski JH; Li DL; Lobb KL; Mason NR; Muehl BS; Nixon JA; Phebus LA; Regoli D; Simmons RM; Threlkeld PG; Waters DC; Gitter BD
J Med Chem; 1996 Feb; 39(3):736-48. PubMed ID: 8576917
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
